---
title: "Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296100635.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-08-17T10:47:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296100635.md)
  - [en](https://longbridge.com/en/news/296100635.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296100635.md)
generator: "portal-rs"
---

# Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [LNTH.US](https://longbridge.com/en/quote/LNTH.US.md)

## Related News & Research

- [Is FDA Approval Of TAUKLARIFY Alzheimer’s Tau PET Agent Altering The Investment Case For Lantheus (LNTH)?](https://longbridge.com/en/news/296889028.md)
- [232,597 Shares in Lantheus Holdings, Inc. $LNTH Acquired by William Blair Investment Management LLC](https://longbridge.com/en/news/296698524.md)
- [SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race](https://longbridge.com/en/news/297220838.md)
- [Netflix parts ways with a key ad exec in a leadership shake-up. Read the leaked memo from its ad chief.](https://longbridge.com/en/news/296834043.md)
- [Kynexis pockets €97m to advance cognition-focused schizophrenia drug](https://longbridge.com/en/news/296501085.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**